CD20(Anti-Cluster of Differentiate 20) 요법에서 유블리툭시맙으로 전환 시 효능 유지를 평가하기 위한 연구 (ENHANCE)
Anti-CD20 요법에서 Ublituximab으로 전환 시 효능 유지 평가
The primary purpose of this phase 3b study is to assess the efficacy of a modified regimen of ublituximab in participants with relapsing multiple sclerosis (RMS) as measured by T1 Gadolinium (Gd)-enhancing lesions in Part A; PK in Part B along with efficacy of ublituximab as measured by T1 Gd-enhancing lesions in participants who had a suboptimal experience on prior anti-CD20 therapy in Part C. The study consists of 3 parts: Part A is single-armed and open-label, Part B is randomized, double-blind, placebo-controlled, and Part C is single-armed and open-label.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 3단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: TG Therapeutics Clinical Support Team
- 전화번호: 1-877-575-8489
- 이메일: clinicalsupport@tgtxinc.com
연구 장소
-
-
Alabama
-
Birmingham, Alabama, 미국, 35209
- 모병
- TG Therapeutics Investigational Trial Site
-
Cullman, Alabama, 미국, 35058
- 모병
- TG Therapeutics Investigational Trial Site
-
-
California
-
Orange, California, 미국, 92697
- 모병
- TG Therapeutics Investigational Trial Site
-
-
Colorado
-
Fort Collins, Colorado, 미국, 80528
- 모병
- TG Investigational Site
-
-
District of Columbia
-
Washington D.C., District of Columbia, 미국, 20007
- 모병
- TG Therapeutics Investigational Trial Site
-
-
Florida
-
Tampa, Florida, 미국, 33612
- 모병
- TG Therapeutics Investigational Trial Site
-
-
Georgia
-
Atlanta, Georgia, 미국, 30309
- 모병
- TG Therapeutics Investigational Trial Site
-
Atlanta, Georgia, 미국, 30322
- 모병
- TG Therapeutics Investigational Trial Site
-
Savannah, Georgia, 미국, 31406
- 모병
- TG Therapeutics Investigational Trial Site
-
-
Illinois
-
Chicago, Illinois, 미국, 60612
- 모병
- TG Therapeutics Investigational Trial Site
-
-
Indiana
-
Indianapolis, Indiana, 미국, 46256
- 모병
- TG Therapeutics Investigational Trial Site
-
-
Iowa
-
Iowa City, Iowa, 미국, 52242
- 모병
- TG Therapeutics Investigational Trial Site
-
-
Kansas
-
Overland Park, Kansas, 미국, 66212
- 완전한
- TG Therapeutics Investigational Trial Site
-
Overland Park, Kansas, 미국, 66205
- 모병
- TG Therapeutics Investigational Trial Site
-
-
Maryland
-
Lutherville, Maryland, 미국, 21093
- 모병
- TG Therapeutics Investigational Trial Site
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 70809
- 모병
- TG Therapeutics Investigational Trial Site
-
Boston, Massachusetts, 미국, 00002
- 모병
- TG Therapeutics Investigational Trial Site
-
Foxborough, Massachusetts, 미국, 02035
- 모병
- TG Therapeutics Investigational Trial Site
-
North Worcester, Massachusetts, 미국, 01655
- 모병
- TG Therapeutics Investigational Trial Site
-
Wellesley, Massachusetts, 미국, 02481
- 모병
- TG Therapeutics Investigational Trial Site
-
-
Michigan
-
Farmington, Michigan, 미국, 48334
- 모병
- TG Investigational Site
-
-
Minnesota
-
Golden Valley, Minnesota, 미국, 55422
- 모병
- TG Therapeutics Investigational Trial Site
-
Plymouth, Minnesota, 미국, 55446
- 모병
- TG Therapeutics Investigational Trial Site
-
-
Missouri
-
St Louis, Missouri, 미국, 63131
- 모병
- TG Therapeutics Investigational Trial Site
-
-
New York
-
New York, New York, 미국, 10025
- 모병
- TG Therapeutics Investigational Trial Site
-
New York, New York, 미국, 11021
- 모병
- TG Therapeutics Investigational Trial Site
-
-
North Carolina
-
Charlotte, North Carolina, 미국, 28204
- 모병
- TG Therapeutics Investigational Trial SiteCharlotte
-
Raleigh, North Carolina, 미국, 27607
- 모병
- TG Therapeutics Investigational Trial Site
-
-
Ohio
-
Cincinnati, Ohio, 미국, 45212
- 모병
- TG Therapeutics Investigational Trial Site
-
Cleveland, Ohio, 미국, 44195
- 모병
- TG Therapeutics Investigational Trial Site
-
Dayton, Ohio, 미국, 45417
- 모병
- TG Therapeutics Investigational Trial Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, 미국, 73104
- 모병
- TG Therapeutics Investigational Trial Site
-
-
South Carolina
-
Greenville, South Carolina, 미국, 29605
- 모병
- TG Therapeutics Investigational Trial Site
-
-
Tennessee
-
Knoxville, Tennessee, 미국, 37922
- 모병
- TG Therapeutics Investigational Trial Site
-
-
Texas
-
Houston, Texas, 미국, 77030
- 완전한
- TG Therapeutics Investigational Trial Site
-
-
Utah
-
Salt Lake City, Utah, 미국, 84103
- 모병
- TG Therapeutics Investigational Trial Site
-
-
Virginia
-
Vienna, Virginia, 미국, 22182
- 모병
- TG Therapeutics Investigational Trial Site
-
-
Washington
-
Kirkland, Washington, 미국, 98034
- 모병
- TG Therapeutics Investigational Trial Site
-
Seattle, Washington, 미국, 98109
- 모병
- TG Therapeutics Investigational Trial Site
-
Spokane, Washington, 미국, 99208
- 모병
- TG Therapeutics Investigational Trial Site
-
-
Wisconsin
-
Milwaukee, Wisconsin, 미국, 53226
- 모병
- TG Therapeutics Investigational Trial Site
-
-
-
-
-
Bydgoszcz, 폴란드, 85-796
- 모병
- TG Therapeutics Investigational Trial Site
-
Katowice, 폴란드, 40-555
- 모병
- TG Therapeutics Investigational Trial Site
-
Kielce, 폴란드, 25-726
- 모병
- TG Therapeutics Investigational Trial Site
-
Krakow, 폴란드, 31-826
- 모병
- TG Therapeutics Investigational Trial Site
-
Lodz, 폴란드, 90-324
- 모병
- TG Therapeutics Investigational Trial Site
-
Olsztyn, 폴란드, 10-561
- 모병
- TG Therapeutics Investigational Trial Site
-
Poznan, 폴란드, 61-583
- 모병
- TG Therapeutics Investigational Trial Site
-
Warsaw, 폴란드, 04-141
- 모병
- TG Therapeutics Investigational Trial Site
-
Zabrze, 폴란드
- 모병
- TG Therapeutics Investigational Trial Site
-
Żory, 폴란드, 44-240
- 모병
- TG Therapeutics Investigational Trial Site
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Diagnosis of RMS (2017 Revised McDonald criteria).
-
Participants must meet one of the following prior treatment definitions:
- Participants naïve to treatment.
- Participants previously treated with a disease modifying therapy (DMT) who have discontinued treatment prior to consent and meet the washout requirements.
-
Expanded Disability Status Scale (EDSS) score ≤ 5.5 at screening.
-
Neurologically stable for > 30 days prior to first dose of ublituximab.
-
Female participants of childbearing potential must consent to use a medically acceptable method of contraception from consent, throughout the study period, and for 6 months after the last dose of ublituximab.
-
Part C: participants currently treated with an anti-CD20 agent for at least 6 months and meet the washout requirements prior to W1D1.
-
Part C: Discontinuation of current anti-CD20 must be due to suboptimal experience
Exclusion Criteria:
- History of any serious 3 Infusion Related Reaction (IRR) on prior anti-CD20 therapy.
- Primary-progressive multiple sclerosis (PPMS) or inactive Secondary Progressive MS (SPMS).
- Active chronic (or stable but treated with immune therapy) disease of the immune system other than MS (e.g., rheumatoid arthritis, scleroderma, Sjögren's syndrome, Crohn's disease, ulcerative colitis, etc.) or immunodeficiency syndrome (hereditary immune deficiency, drug-induced immune deficiency, etc.).
- Current evidence or known history of clinically significant infection, including: chronic, recurrent, or ongoing active viral, bacterial, or fungal infectious disease requiring long term systemic treatment such as, but not limited to chronic urinary tract infection, chronic pulmonary infection with bronchiectasis, tuberculosis, or active hepatitis C virus (HCV).
- Previous serious opportunistic or atypical infection.
- Evidence of chronic active or history of hepatitis B virus (HBV) infection as evidenced by a detectable hepatitis B surface antigen (HBsAg), or positive hepatitis B core antibody (HBcAb), or chronic hepatitis C infection. Participants with positive hepatitis C virus antibody (HCV Ab) are eligible only if polymerase chain reaction (PCR) is negative for HCV ribonucleic acid (RNA).
- History or evidence (clinical, radiological, or biomarker) of suspected or confirmed progressive multifocal leukoencephalopathy (PML).
- Receipt of any live or live-attenuated vaccines (including vaccines for varicella-zoster virus or measles) within 4 weeks prior to first study drug administration.
- Participants requiring treatment with intravenous immune globulin (IVIG) for decreased immunoglobulins within the 12 months prior to W1D1.
- Any active malignancies other than adequately treated basal, squamous cell or in situ carcinoma.
- Participants who have ever received ublituximab, alemtuzumab, cyclophosphamide, mitoxantrone, cladribine, or daclizumab (including for non-MS indications).
Note: Other Inclusion/Exclusion criteria may apply.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Part A: Ublituximab
Participants will receive a modified regimen of ublituximab including infusions on Day 1 of Week 1 (W1D1), Day 15, if applicable, and ublituximab 450 milligrams (mg) infusion at Week 24. With Protocol Version 6.0, enrollment in Part A was closed. |
Administered as an intravenous (IV) infusion.
다른 이름들:
|
|
실험적: Part B: Ublituximab /Placebo (Treatment Arm A)
Participants will receive 600 mg of ublituximab on W1D1 followed by a placebo infusion on Day 15 and 450 mg ublituximab infusion at Week 24. With Protocol Version 7.0, enrollment in Part B will be closed. |
IV infusion Administered as an intravenous (IV) infusion.
다른 이름들:
|
|
실험적: Part B: Ublituximab (Treatment Arm B)
Participants will receive 150 mg of ublituximab on W1D1 followed by 450 mg on Day 15 and at Week 24. With Protocol Version 7.0, enrollment in Part B will be closed. |
Administered as an intravenous (IV) infusion.
다른 이름들:
|
|
실험적: Part C: Ublituximab (Treatment Arm C)
Participants will receive 150 mg of ublituximab on W1D1, followed by 450 mg on Day 15 and at Week 24. |
Administered as an intravenous (IV) infusion.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
파트 B: 유블리툭시맙의 첫 16주 동안의 곡선하 면적(AUC0-W16)
기간: 투여 전 및 제16주까지의 여러 시점
|
투여 전 및 제16주까지의 여러 시점
|
|
|
Part A and Part C: Percentage of Participants With no Change or Reduction in Number of T1 Gd-Enhancing Lesions From Baseline to Week 48
기간: Baseline up to Week 48
|
The Gd-enhancing T1 lesions will be evaluated using magnetic resonance imaging (MRI) technique. |
Baseline up to Week 48
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Parts A: Percentage of Participants Free of T1 Gd-Enhancing Lesions
기간: Week 48
|
The Gd-enhancing T1 lesions will be evaluated using MRI technique. |
Week 48
|
|
Parts A and B: Percentage of Participants Experiencing Infusion Related Reactions (IRRs)
기간: Up to Week 48
|
IRRs are defined as infusion related adverse events (AEs) that occur within one day of an infusion and resolve within 7 days. IRRs will be reported by investigator. |
Up to Week 48
|
|
Parts A: Change From Baseline in Treatment Satisfaction Questionnaire for Medication (TSQM-9) Scores
기간: Part A: Baseline, Week 24 and Week 48
|
The TSQM-9 is a 9-item questionnaire with 3 domains: Satisfaction, convenience, and effectiveness. |
Part A: Baseline, Week 24 and Week 48
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- TG1101-RMS401
- 2024-519284-18-00 (기타 식별자: EU CT Number)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .